0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Demonstration of Glucocorticoid Receptors in Human Mammary Carcinomas

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tumor regression is sometimes observed during glucocorticoid treatment of patients with breast cancer. The possibility of a direct tumor-growth-suppressing effect, mediated by steroid-hormone receptors, cannot be excluded. A <sup>3</sup>H-dexamethasone-binding component in the cytoplasmatic fraction of human breast cancers was studied by agar-gel electrophoresis. Of 90 samples, 51% contained a significant amount of an apparent glucocorticoid receptor. In two specimens from metastases, in which a preexisting lymph node structure was almost completely replaced by tumor tissue, the glucocorticoid receptor character of the binding component was studied extensively. The component satisfied the steroid-hormone receptor criteria in being a high affinity (K<sub>d</sub> ∼ 4 – 9 × 10<sup>- 9</sup> M), low capacity binder. Competition studies with excess unlabelled steroids of different classes confirmed the specific glucocorticoid receptor character of the component. Both tumors contained also estrogen and androgen receptors and one contained an apparent progestin receptor.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          1663-2818
          1663-2826
          1977
          1977
          25 November 2008
          : 8
          : 2
          : 107-116
          Affiliations
          Departments of Biochemistry and Clinical Endocrinology, Rotterdamsch Radio-Therapeutisch Instituut, Dr. Daniel den Hoed Kliniek, Rotterdam
          Article
          178787 Horm Res 1977;8:107–116
          10.1159/000178787
          908552
          © 1977 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 10
          Categories
          Paper

          Comments

          Comment on this article